This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Allen, N. E. Articles by Kaaks, R. Search for Related Content PubMed PubMed Citation Articles by Allen, N. E. Articles by Kaaks, R.

Serum Insulin-like Growth Factor (IGF)-I and IGF-Binding Protein-3 Concentrations and Prostate Cancer Risk: Results from the European Prospective Investigation into Cancer and Nutrition

¹ Cancer Research UK Epidemiology Unit, University of Oxford, Oxford, United Kingdom; ² IARC, Lyon, France; ³ Division of Cancer Epidemiology, Deutsches Krebsforschungszentrum, Heidelberg, Germany; ⁴ Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany; ⁵ Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark; ⁶ Medical Department V, Aarhus University Hospital, Aarhus, Denmark; ⁷ Department of Clinical Epidemiology, Aalborg Hospital, Aarhus University Hospital, Aalborg, Denmark; ⁸ Departments of Epidemiology and Urology, University Medical Centre Nijmegen, Nijmegen, the Netherlands; ⁹ Centre for Nutrition and Health, National Institute for Public Health and the Environment, Bilthoven, the Netherlands; ¹⁰ Medical Research Council Dunn Human Nutrition Unit and Medical Research Council Centre for Nutritional Epidemiology in Cancer Prevention and Survival, Department of Public Health and Primary Care, University of Cambridge; ¹¹ Clinical Gerontology Unit, University of Cambridge, School of Clinical Medicine, Addenbrooke's Hospital, Cambridge, United Kingdom; ¹² Cancer Registry, Azienda Ospedaliera "Civile M.P. Arezzo," Ragusa, Italy; ¹³ Epidemiology Unit, Istituto Nazionale dei Tumori, Milan, Italy; ¹⁴ Dipartimento di Medicina Clinica e Sperimentale, Università di Napoli Federico II, Naples, Italy; ¹⁵ Department of Biomedical Science and Human Oncology, Center for Cancer Prevention-Piemonte, Torino, Italy; ¹⁶ Molecular and Nutritional Epidemiology Unit, Center for Study and Prevention of Cancer, Scientific Institute of Tuscany, Florence, Italy; ¹⁷ Public Health and Health Planning Directorate, Asturias, Spain; ¹⁸ Public Health Institute of Navarra, Pamplona, Spain; ¹⁹ Department of Epidemiology, Murcia Health Council, Murcia, Spain; ²⁰ Public Health Department of Gipuzkoa, Basque Government, San Sebastian, Spain; ²¹ Department of Epidemiology, Catalan Institute of Oncology, Barcelona, Spain; ²² Escuela Andaluza de Salud Publica, Granada, Spain; ²³ Department of Hygiene and Epidemiology, University of Athens Medical School; ²⁴ Hellenic Health Foundation, Athens, Greece; and ²⁵ Department of Epidemiology and Public Health, Imperial College, London, United Kingdom

Requests for reprints: Naomi E. Allen, Cancer Research UK Epidemiology Unit, University of Oxford, Oxford OX3 7LF, United Kingdom. Phone: 44-1865-289600; Fax: 44-1865-289610. E-mail: naomi.allen{at}ceu.ox.ac.uk

Background: Some studies suggest that elevated serum insulin-like growth factor (IGF)-I concentrations are associated with an increased risk of prostate cancer and, in particular, with an increased risk of advanced-stage prostate cancer.

Methods: We analyzed the association between prediagnostic serum concentrations of IGF-I and IGF-binding protein-3 (IGFBP-3) and prostate cancer risk in a case-control study nested in the European Prospective Investigation into Cancer and Nutrition. This study includes 630 incident prostate cancer cases and 630 matched control subjects. Odds ratios and their 95% confidence intervals (95% CI) were calculated for prostate cancer risk associated with increasing IGF-I and IGFBP-3 concentrations using conditional logistic regression.

Results: The risk of total prostate cancer in the highest versus the lowest third of serum peptide concentration was 1.35 (95% CI, 0.99-1.82; P_trend = 0.08) for IGF-I, 1.39 (95% CI, 1.02-1.89; P_trend = 0.12) for the IGF-I residuals after adjusting for IGFBP-3, 1.22 (95% CI, 0.92-1.64; P_trend = 0.38) for IGFBP-3, and 1.01 (95% CI, 0.74-1.37; P_trend = 0.75) for the IGFBP-3 residuals after adjusting for IGF-I. There was no significant difference in the association of peptide hormones and prostate cancer by stage of disease, although the association of serum IGF-I concentration with risk was slightly stronger for advanced-stage disease; the odds ratio for the highest versus the lowest third was 1.65 (95% CI, 0.88-3.08; P_trend = 0.21) for IGF-I and 1.76 (95% CI, 0.92-3.40; P_trend = 0.11) for IGF-I adjusted for IGFBP-3.

Conclusions: In this large nested case-control study, serum IGF-I concentration is not strongly associated with prostate cancer risk, although the results are compatible with a small increase in risk, particularly for advanced-stage disease; no association for IGFBP-3 was observed. (Cancer Epidemiol Biomarkers Prev 2007;16(6):1121–7)

This article has been cited by other articles:

				F. L. Crowe, T. J. Key, N. E. Allen, P. N. Appleby, A. Roddam, K. Overvad, H. Gronbaek, A. Tjonneland, J. Halkjaer, L. Dossus, et al. The Association between Diet and Serum Concentrations of IGF-I, IGFBP-1, IGFBP-2, and IGFBP-3 in the European Prospective Investigation into Cancer and Nutrition Cancer Epidemiol. Biomarkers Prev., May 1, 2009; 18(5): 1333 - 1340. [Abstract] [Full Text] [PDF]

				M. Johansson, J. D. McKay, F. Wiklund, S. Rinaldi, G. Hallmans, K. Balter, H.-O. Adami, H. Gronberg, P. Stattin, and R. Kaaks Genetic Variation in the SST Gene and its Receptors in Relation to Circulating Levels of Insulin-Like Growth Factor-I, IGFBP3, and Prostate Cancer Risk Cancer Epidemiol. Biomarkers Prev., May 1, 2009; 18(5): 1644 - 1650. [Abstract] [Full Text] [PDF]

				G. N. Farhat, E. Taioli, J. A. Cauley, J. M. Zmuda, E. Orwoll, D. C. Bauer, T. J. Wilt, A. R. Hoffman, T. M. Beer, J. M. Shikany, et al. The Association of Bone Mineral Density with Prostate Cancer Risk in the Osteoporotic Fractures in Men (MrOS) Study Cancer Epidemiol. Biomarkers Prev., January 1, 2009; 18(1): 148 - 154. [Abstract] [Full Text] [PDF]

				T. Pischon, H. Boeing, S. Weikert, N. Allen, T. Key, N. F. Johnsen, A. Tjonneland, M. T. Severinsen, K. Overvad, S. Rohrmann, et al. Body Size and Risk of Prostate Cancer in the European Prospective Investigation into Cancer and Nutrition Cancer Epidemiol. Biomarkers Prev., November 1, 2008; 17(11): 3252 - 3261. [Abstract] [Full Text] [PDF]

				A. W. Roddam, N. E. Allen, P. Appleby, T. J. Key, L. Ferrucci, H. B. Carter, E. J. Metter, C. Chen, N. S. Weiss, A. Fitzpatrick, et al. Insulin-like Growth Factors, Their Binding Proteins, and Prostate Cancer Risk: Analysis of Individual Patient Data from 12 Prospective Studies Ann Intern Med, October 7, 2008; 149(7): 461 - 471. [Abstract] [Full Text] [PDF]

				C. Braconi, R. Bracci, I. Bearzi, F. Bianchi, S. Sabato, A. Mandolesi, L. Belvederesi, S. Cascinu, N. Valeri, and R. Cellerino Insulin-like growth factor (IGF) 1 and 2 help to predict disease outcome in GIST patients Ann. Onc., July 1, 2008; 19(7): 1293 - 1298. [Abstract] [Full Text] [PDF]

				Y. Minami, T. Tochigi, S. Kawamura, H. Tateno, S. Hoshi, Y. Nishino, and M. Kuwahara Height, Urban-born and Prostate Cancer Risk in Japanese Men Jpn. J. Clin. Oncol., March 1, 2008; 38(3): 205 - 213. [Abstract] [Full Text] [PDF]

				M. J. Borugian, J. J. Spinelli, Z. Sun, L. N. Kolonel, I. Oakley-Girvan, M. D. Pollak, A. S. Whittemore, A. H. Wu, and R. P. Gallagher Prostate Cancer Risk in Relation to Insulin-like Growth Factor (IGF)-I and IGF-Binding Protein-3: A Prospective Multiethnic Study Cancer Epidemiol. Biomarkers Prev., January 1, 2008; 17(1): 252 - 254. [Full Text] [PDF]